TrialPath
Recruiting

The COMPASSION Study

NCT06507930 · Dana-Farber Cancer Institute
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
The COMPASSION Study: Applying Telehealth to Innovate and Strengthen Connections for Patients With Metastatic Breast Cancer Receiving Hospice Care
About this study
The aim of this research study is to better understand the in-home hospice experience for participants, caregivers, hospice nurses, and oncology providers by conducting telehealth check-ins between participants and caregivers and oncology care teams. Study procedures include giving verbal consent to participate and a one-time survey delivered by email or phone call. About 200 people, which includes 50 participants, 50 caregivers, 50 hospice nurses, and about 50 oncology providers, are expected to participate in this research study.
Eligibility criteria
Inclusion Criteria: * Patient of any gender with unresectable locally advanced or metastatic breast cancer * Eligible for in-home hospice services and referred by DFCI clinical team to in-home hospice \</= 1 week before enrollment * Ability to conduct video or phone check-ins, even if assistance required. * Able to provide verbal consent with a willingness to take a survey at 4-6 weeks, if medically able * Hospice setting is within Massachusetts * Non-English language allowed but interpreter services must be present at each meeting and will be coordinated by scheduling team * Willingness to provide a caregiver/loved one's contact information for survey contact at 4 weeks after enrollment Exclusion Criteria: * Unable to provide verbal consent * Hospice care planned outside of a home setting (note: if participants start out in a home hospice setting but later transition their hospice care to an inpatient setting, enrollment is allowed as long as they started in a home setting) * Hospice setting outside of Massachusetts * Individuals who are under the age of 18, as this is not a project focused on pediatric patients.
Study design
Enrollment target: 200 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2024-09-01
Estimated completion: 2027-03-01
Last updated: 2025-10-09
Interventions
Other: Telehealth Hospice Visits
Primary outcomes
  • Proportion of Participant Intervention Completion (Up to 4 weeks)
Sponsor
Dana-Farber Cancer Institute · other
Contacts & investigators
ContactClaire Smith, MD · contact · claire_smith@dfci.harvard.edu · 617-632-3800
InvestigatorClaire Smith, MD · principal_investigator, Dana-Farber Cancer Institute
All locations (1)
Dana-Farber Cancer InstituteRecruiting
Boston, Massachusetts, United States
The COMPASSION Study · TrialPath